Curated news and analysis on clinical trials, drug approvals, and medical research.
A Feb. 20, 2026 study in the Journal of Experimental Medicine identified CD8 T cell-derived TNF and TNFR2 signaling as drivers of ICI-related myocarditis in mice. Blocking TNFR2 prevented the inflammatory cycle in the heart.
Sunfield Masterplanned Community has been approved through the Government’s Fast-track process in Auckland. The project includes about 3,854 homes and is projected to deliver up to $3.2 billion to the economy.
Cabozantinib plus metronomic temozolomide showed a 15% response rate and 28.5-month median progression-free survival in a phase 2 NET study. A separate analysis found cabozantinib cost-effective for pancreatic NETs, but not extrapancreatic NETs, in China and the U.S.
The FDA approved Endospan’s NEXUS Aortic Arch Stent Graft, enabling US commercial launch. Approval was supported by one-year TRIOMPHE study results in high-risk surgical patients.
The REMEDY Act would limit the Hatch-Waxman Act’s 30-month stay to one Orange Book-listed patent and require that patent to be designated in advance. The bill was reintroduced in the Senate on July 31, 2025 and is again in committee.
Novartis agreed to sell its 70.68% stake in Novartis India Ltd. for 14.46 billion rupees. The buyers also launched a 26% open offer at 860.84 rupees per share.
The metabolomics and mass spectrometry markets are projected to expand as demand rises for precision medicine, biomarker discovery, and multi-omics research. Market reports valued metabolomics at USD 3.7 billion in 2024 and mass spectrometry at USD 7.24 billion in 2025.
Daiichi Sankyo is collaborating with BostonGene to integrate AI-driven translational intelligence into an antibody drug conjugate development programme. The work is aimed at biomarker discovery, response prediction, patient selection and trial design across its cancer pipeline.
EMA India Limited has started a postal ballot to seek shareholder approval for appointing Apurva Shivaji Adhalrao and Rajendra Senapati to its board. Remote e-voting runs from April 11 to May 10, 2026.
A study identified host-response plasma protein candidate biomarkers to predict venous thromboembolism risk after pleural mesothelioma surgery. The exploratory cohort included 18 patients.
Omeros reported initial nonhuman primate data for OncotoX-AML in acute myeloid leukemia. One treatment course reduced myeloid progenitor cells by up to 99% and was well tolerated.
USD/CAD held near 1.3700 on Thursday as the US Dollar stayed firm after January FOMC minutes. Fed officials signaled no rush to cut rates, while the BoC is expected to keep rates at 2.25% through 2026.
A Delphi consensus of 23 experts identified Zostavax, sildenafil and riluzole as high-priority candidates for Alzheimer disease clinical trials. Caregivers ranked the herpes zoster vaccine highest for acceptability and perceived benefit–risk balance.
Deep learning studies using MRI, genetics and longitudinal imaging reported improved dementia risk prediction and mapped dynamic brain-region changes during Alzheimer’s disease progression.
BridgeBio Pharma reported long term acoramidis data in transthyretin amyloid cardiomyopathy and submitted a US FDA NDA for BBP-418 in LGMD2I/R9. BBP-418 could become the first approved therapy for the disease if cleared.
The CDC reported six new influenza-associated pediatric deaths in Week 6 of 2026, bringing the 2025-2026 U.S. season total to 71. About 90% of deaths with known vaccination status were in children not fully vaccinated.
Sift Biosciences closed an oversubscribed $3.7 million pre-seed round to advance a peptide immunotherapy platform designed to activate pre-existing memory T cells. The financing will fund in vivo studies, expansion of its AI-powered discovery engine, and oncology lead selection.
Durvalumab has been approved for rollout on the NHS for muscle-invasive bladder cancer. In a trial of more than 1,000 patients, it cut the risk of progression by 32% versus standard care.
Champions Oncology said it will present eight poster presentations at AACR 2026 in San Diego on April 17-22. The studies cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs and CAR-T therapies.
The FDA accepted Replimune’s BLA resubmission for RP1 plus nivolumab in advanced melanoma. The agency set an April 10, 2026 PDUFA date under a Class II resubmission timeline.
